Afutuzumab ELISA Kit

Catalog No.

KDC90702

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

0.31-5 μg/mL

Sensitivity

0.156 μg/ml

Precision

CV<20%

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Alternative Names

GA101,RG7159,RO5072759,CAS: 949142-50-1

Background

Afutuzumab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B lymphocytes. Upon binding to CD20, obinutuzumab mediates B-cell lysisthrough (1) engagement of immune effector cells (2) by directly activating intracellular death signaling pathways (direct cell death), and/or (3) activation of the complement cascade. The immune effector cell mechanisms include antibody-dependent cellular cytotoxicity (ADCC) and antibodydependent cellular phagocytosis.As an antibody with reduced fucose content, obinutuzumab induces greater ADCC activity than rituximab in vitro using human cancer cell lines. Afutuzumab also demonstrated an increased ability to induce direct cell death when compared to rituximab. Afutuzumab binds to FcγRIII using purified proteins with a higher affinity than rituximab. Afutuzumab and rituximab bind with similar affinity to overlapping epitopes on CD20.

Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia., PMID:40515863

Chemotherapy-free combination of ibrutinib and obinutuzumab for untreated advanced follicular lymphoma: results of a phase II study from the German Lymphoma Alliance., PMID:40501414

Advances and challenges in leukemia treatment: A focus on monoclonal antibodies and emerging therapies., PMID:40486885

In active lupus nephritis, adding obinutuzumab to standard therapy increased complete renal response rates at 76 wk., PMID:40456159

Short-duration infusion obinutuzumab with venetoclax in chronic lymphocytic leukemia: a prospective observational study., PMID:40453137

Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?, PMID:40427101

Obinutuzumab in Patients With Active Lupus Nephritis: A Meta-Analysis., PMID:40424616

Obinutuzumab-Induced Inflammatory Bowel Disease-Like Colitis., PMID:40421460

Cardiac Events in Three Phase 3 Randomized Trials Including Acalabrutinib in Chronic Lymphocytic Leukemia., PMID:40413154

Successful treatment of pemphigus vulgaris with obinutuzumab., PMID:40406957

Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy., PMID:40388905

Early caplacizumab and obinutuzumab enable successful treatment of relapsing thrombotic thrombocytopenic purpura without therapeutic plasma exchange: a case report., PMID:40356910

Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403., PMID:40355425

Clinical experience and safety of venetoclax in the treatment of patients with chronic lymphocytic leukemia - real-world data from a hemato-oncology center., PMID:40353625

Obinutuzumab as a Promising Treatment for Membranous Nephropathy., PMID:40352879

CRISPRi screening identifies PIKfyve as a co-therapeutic target for obinutuzumab., PMID:40342289

Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy., PMID:40336511

[Seronegativity and anti-CD20: When a treatment compromises the diagnosis]., PMID:40312237

Obinutuzumab for treatment of membranous nephropathy in patients positive and negative for the phospholipase A2 receptor antibody: case reports., PMID:40303416

Obinutuzumab in Rituximab-Intolerant Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Patients., PMID:40303206

Immunotherapy for autoimmune encephalitis., PMID:40301313

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group., PMID:40285420

Osteonecrosis of the Jaw Associated with Obinutuzumab in a Patient with Preceding Follicular Non-Hodgkin's Lymphoma., PMID:40278317

How we manage immune-mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance., PMID:40270461

Successful Treatment of Ocular Post-Transplant Lymphoproliferative Disorder with Obinutuzumab in an 8-Year-Old Boy Following Kidney Transplant: A Case Report., PMID:40255019

An autopsy for persistent coronavirus disease 2019 pneumonia during follicular lymphoma treatment: A case report., PMID:40254437

Clinical characteristics, treatment patterns and outcomes of patients with follicular lymphoma in Colombia: a real-world evidence cohort study., PMID:40227475

Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies., PMID:40225374

Obinutuzumab-induced Acute Thrombocytopenia Mimicking Immune Thrombocytopenia in a Patient with Follicular Lymphoma., PMID:40222942

Obinutuzumab in focal segmental glomerulonephritis resistant to treatment., PMID:40221341

AMPLIFY: A second-generation BTK inhibitor for fixed-duration therapy in chronic lymphocytic leukemia., PMID:40220751

B cell depletion in lupus nephritis: From disappointments to hopes, despite some concerns., PMID:40220749

A New Pulmonary Nodule in a Patient With a History of Lymphoma., PMID:40210319

Obinutuzumab: a new frontier in the treatment of refractory idiopathic membranous nephropathy., PMID:40205126

Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in treatment-naive CLL in the 6-year Follow-up of ELEVATE-TN., PMID:40198878

Obinutuzumab in patients with repeated lupus nephritis flares: A case series., PMID:40186329

Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study., PMID:40181090

A pilot study to determine the feasibility and safety of pharmacist and nurse driven management of venetoclax ramp-up in patients with chronic lymphocytic leukemia., PMID:40170466

Treatment of nephrotic syndrome with anti-CD20 therapies in pregnancy: a case series and review of the literature., PMID:40148078

Preclinical B cell depletion and safety profile of a brain-shuttled crystallizable fragment-silenced CD20 antibody., PMID:40118783

Zanubrutinib, venetoclax, and obinutuzumab in R/R CLL., PMID:40111334

The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease., PMID:40104551

Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia., PMID:40101233

Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease., PMID:40101168

Upfront fixed-duration treatment strategies for chronic lymphocytic leukemia in Arab populations: a position statement from the Gulf region., PMID:40078401

Real-World Effectiveness of Frontline Treatments Among Patients with Chronic Lymphocytic Leukemia: Results from ConcertAI., PMID:40075647

Anti-CD20 maintenance strategies to face the challenge of COVID-19 pandemic in follicular lymphoma: results from the R-FolSTOP multicentre Italian study., PMID:40074837

Bilateral drusenoid deposits with subretinal fluid and cystoid macular edema in a serum anti-phospholipase A2 receptor antibody positive patient: A case report., PMID:40061915

[The combined regimen based on obinutuzumab plus glucocorticoid for 4 cases of relapsed iTTP]., PMID:40059685

Obinutuzumab effective for lupus nephritis., PMID:40055568

Document Download

Afutuzumab ELISA Kit.pdf